Equity Profile

RMD

ResMed Inc.

Health CareHealth Care Equipment$28.1B

Aug6Thu

Pre-Earnings Brief

UpcomingQ4-2026After Close5:00 PM EDT

Company Snapshot

ResMed Inc. (RMD) operates in the health care sector, focusing on equipment and software solutions for people with sleep apnea and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and meet demand in the health care equipment industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

ResMed Inc. (RMD) operates in the health care sector, focusing on equipment and software solutions for people with sleep apnea and chronic obstructive pulmonary disease (COPD). The company plays a crucial role in improving patient outcomes through innovative technology, particularly as demand for respiratory care continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In Q3-2026, ResMed reported an EPS of $2.86, surpassing estimates by 2.58%. Despite the positive earnings surprise, the stock saw a modest increase of 0.89% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for ResMed's upcoming earnings are cautious, given the lack of analyst estimates and management guidance. Investors will be looking for any signs of growth in a competitive health care market.

Bull Case

If ResMed continues its trend of beating EPS estimates, it could signal strong operational performance and market demand, potentially leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative market reaction, especially given the current market volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q4-2026?

Given ResMed's history of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.

How is ResMed addressing competition in the health care equipment sector?

Understanding the company's strategy in a competitive landscape will be crucial for assessing future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ResMed's ability to capture market share in the growing respiratory care segment, particularly as awareness of sleep apnea increases.

Supporting Evidence

ResMed has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a significant move, suggesting that investors are anticipating volatility, which could favor a positive outcome.

Historical trends show that ResMed often reacts positively to earnings beats, which could be overlooked.

Key Risk

If the EPS comes in above $2.90, it could challenge current market skepticism about the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining whether ResMed can sustain its growth trajectory amid increasing competition.

Bull Confirmed If

An EPS of $2.90 or higher would confirm strong operational performance and growth.

Bear Confirmed If

An EPS below $2.70 would raise concerns about the company's ability to maintain profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.12%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a potential move of over 5% in either direction, indicating uncertainty about the upcoming earnings report.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests the stock could rise by around 0.21% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management expresses caution, the stock may remain flat or see minor fluctuations.

Miss

If ResMed misses expectations, history suggests a potential decline of around 0.54%, indicating market disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in respiratory care technology.
2Insights into market share growth in key regions.
3Management's outlook on competitive pressures in the health care equipment sector.
4Details on cost management strategies and their impact on margins.
5Any commentary on regulatory changes affecting the industry.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

ResMed Inc. (RMD) operates in the health care sector, focusing on equipment and software solutions for people with sleep apnea and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and meet demand in the health care equipment industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In Q3-2026, ResMed reported an EPS of $2.86, surpassing estimates by 2.58%. Despite the positive earnings surprise, the stock saw a modest increase of 0.89% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If ResMed continues its trend of beating EPS estimates, it could signal strong operational performance and market demand, potentially leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative market reaction, especially given the current market volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q4-2026?

Given ResMed's history of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.

How is ResMed addressing competition in the health care equipment sector?

Understanding the company's strategy in a competitive landscape will be crucial for assessing future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ResMed's ability to capture market share in the growing respiratory care segment, particularly as awareness of sleep apnea increases.

Supporting Evidence

ResMed has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a significant move, suggesting that investors are anticipating volatility, which could favor a positive outcome.

Historical trends show that ResMed often reacts positively to earnings beats, which could be overlooked.

Key Risk

If the EPS comes in above $2.90, it could challenge current market skepticism about the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining whether ResMed can sustain its growth trajectory amid increasing competition.

Bull Confirmed If

An EPS of $2.90 or higher would confirm strong operational performance and growth.

Bear Confirmed If

An EPS below $2.70 would raise concerns about the company's ability to maintain profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.12%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a potential move of over 5% in either direction, indicating uncertainty about the upcoming earnings report.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests the stock could rise by around 0.21% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management expresses caution, the stock may remain flat or see minor fluctuations.

Miss

If ResMed misses expectations, history suggests a potential decline of around 0.54%, indicating market disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in respiratory care technology.
2Insights into market share growth in key regions.
3Management's outlook on competitive pressures in the health care equipment sector.
4Details on cost management strategies and their impact on margins.
5Any commentary on regulatory changes affecting the industry.